Jackie Fairley, BSc, BVSc (Hons), MBA
Chief Executive Officer

Dr Jackie Fairley has more than 20 years of operational experience in the pharmaceutical and biotechnology industries working in business development and senior management roles with companies including CSL and Faulding (now Hospira). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006. Jackie holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in 1989. Whilst at CSL she obtained an MBA from the Melbourne Business School where, as Dux of her final year, she was the recipient of the prestigious Clemenger Medal and a number of other academic prizes. Jackie is also a Graduate of the Australian Institute of Company Directors. Jackie currently sits on the board of the Melbourne Business School, and is a past member of the Federal Government’s Pharmaceutical Industry Working Group and the Federal Ministerial Biotechnology Advisory Council. She is also an advisor to the Carnegie Innovation Fund.

Paul Barrett, BSc (Hons), PhD
Vice President, Business Development
Dr Barrett is jointly responsible for the commercialisation of Starpharma’s dendrimer technology into pharmaceutical and related fields. Since he joined Starpharma in 2005 the Company has signed a series of partnering and commercialisation agreements including a number of collaborations in areas including VivaGel®, drug delivery and in vitro diagnostics. Prior to joining Starpharma he held positions at Nortel Networks, Smiths Industries Aerospace, the University of Oxford and Bookham Technology. Dr Barrett is a co-author on 13 publications in both the physical and biological sciences.

David Owen, BSc (Hons), PhD
Vice President, Research
Dr Owen has extensive experience in medicinal chemistry and biochemistry, and in managing teams focused on commercially directed drug discovery. He has held several positions in the biotech industry, starting with Mimotopes (part of Mitokor Inc.) as a senior chemist, and has worked on projects for several major pharmaceutical companies. He was head of chemistry at Cerylid Biosciences, and later Glykoz, where he headed a team of chemists working on a new class of antibacterial agents. Dr Owen has expertise in many areas of chemistry, including the synthesis of natural products, peptides, carbohydrates and heterocyclic compounds, and has worked across therapeutic areas including type 2 diabetes, antimicrobials and anticancer agents. He is a co-author on 20 publications and 5 patents.

Jeremy Paull, BSc (Hons), PhD
Vice President, Development and Regulatory Affairs
Dr Paull heads up Starpharma’s preclinical and clinical development programs and manages the Company’s interactions with international regulatory authorities. Jeremy also leads Starpharma’s NIH -funded programs, and is responsible for successful collaborations with the Company’s many international research and commercial development partners. Key priorities include the advancement of the VivaGel® standalone product through late-stage development, and the development of the coated condom product. Since joining Starpharma in 2001, Dr Paull’s efforts have been integral to the advancement of the VivaGel® development program.

Malcolm McColl, BVSc(Hons), MBA
Vice President, Business Development
Dr McColl joined Starpharma in 2010 and is jointly responsible for the partnering activities and programs, particularly for pharmaceutical applications of Starpharma’s dendrimer technology. Malcolm has more than 20 years’ experience with global pharmaceutical and biotech companies across Europe, the USA and Asia, and most recently grew the global and EMEA business of Hospira (previously Mayne Pharma) through targeted acquisitions and licensing activities including a successful deal with Chemgenex for rights to Omacetaxine, a proprietary oncology product. Dr McColl has also worked for CSL Animal Health and holds a Bachelor in Veterinary Science from the University of Melbourne and an MBA from Melbourne Business School.

Nigel Baade, BCom , CPA, Grad Dip Arts (Development)
Chief Financial Officer
Mr Baade is a CPA -qualified accountant with extensive experience in the pharmaceutical and biotechnology industries. Appointed to the position on 1 January 2009, he is responsible for the financial control and compliance of the Group. Mr Baade has experience in project and cost management of research activities, commercialisation of global business development opportunities, public and private equity raising and grant funding compliance. Prior to joining Starpharma as Financial Controller in 2006, he has held positions at Hagemeyer, Cerylid Biosciences, Faulding (Hospira) and UMT (Fonterra). He holds qualifications from University of Tasmania and Monash University.

Ben Rogers
Company Secretary
As Company Secretary Mr Rogers is the chief administrative officer of the Company and has the principal role of supporting the work of the Board. He has extensive experience in finance, corporate governance and HR management with CSIRO research laboratories and Co-operative Research Centres in Victoria, South Australia and Western Australia. Mr Rogers was a member of Starpharma’s start-up/IPO management team and has been Company Secretary since February 1998. Until 31 December 2008 his responsibilities also included the role of Chief Financial Officer.